Stock Analysis
Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis
Syndax Pharmaceuticals, Inc. (SNDX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Syndax Pharmaceuticals, Inc. (SNDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 66/100. Momentum is the weakest current factor at 14/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
SNDX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $9.45 |
| AIQ Score | 43/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $848.51M |
| P/E Ratio (TTM) | -3.99 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.55 |
| Revenue (Q3 FY2026) | $83.3M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.77 |
| Volume | 3.18M |
| 52-week range | $9.11-$25.59 |
| RSI 14 | 26.22 |
| 50-Day SMA | $15.27 |
| 200-Day SMA | $19.72 |
| Analyst Price Target | $36.75 |
| Next Earnings | Feb 25, 2027 |
SNDXSyndax Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum14
- Value64
- Quality66
- Risk resilience37
- Sentiment—
SNDX Stock Analysis Summary
Syndax Pharmaceuticals, Inc. (SNDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 66/100. Momentum is the weakest current factor at 14/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, SNDX has AIQ Score of 43/100 with Quality base of 66/100 and fading Momentum at 14/100. Wait for component alignment before adding exposure.
Quality (66/100) leads while Momentum (14/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.94% stock move · SNDX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is SNDX Bullish or Bearish Right Now?
SNDX currently has a bearish overall setup. Quality is the strongest factor at 66/100, while Momentum is weakest at 14/100. The current evidence suggests a bearish setup.
- - Quality is supportive at 66/100.
- - Analyst target implies +288.89% upside from the latest quote.
- - Momentum is weak at 14/100.
- - Risk Resilience is weak at 37/100.
- - Price is -52.08% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (37 vs 6).
Current Consensus
SNDX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 3 neutral, and 37 sell votes. SNDX's 14-day RSI is 26.22, which places the stock in an oversold momentum range. SNDX's beta is 0.77, indicating lower market sensitivity than the broad market.
What Changed in SNDX?
The largest recent change in SNDX is Momentum moving down by 6.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the SNDX Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
SNDX Decision Framework
Public evidence layers, setup checks, and risk context for Syndax Pharmaceuticals, Inc..
Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis
Syndax Pharmaceuticals, Inc. has an AIQ Score of 43/100 in a Bearish regime. Quality is strongest at 66/100. Beta is 0.77, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | SNDX is in a Bearish AIQ regime with score 43/100. |
| Signal Conflict | The primary conflict is that quality leads at 66/100 while momentum lags at 14/100. |
| Factor Evidence | Momentum 14/100 · Value 64/100 · Quality 66/100 · Risk 37/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 66/100.
Momentum is 14/100 and RSI (14) is 26.2.
SNDX is in a Bearish regime at 43/100.
Risk factor is 37/100 with beta 0.77 and annual volatility 57.16%.
Current conflict: quality leads at 66/100 while momentum lags at 14/100.
SNDX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
SNDX Fundamentals
SNDX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
SNDX Technical Analysis
SNDX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
SNDX Stock Catalysts
Track SNDX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
SNDX Dividend Analysis
SNDX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
SNDX Financial Data
SNDX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
SNDX Risk Analysis
SNDX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
SNDX Stock News
SNDX stock news, market tone, recent headlines, and catalyst context.
SNDX vs Biotechnology Peers
Current peer cohort: SNDX · SRRK · STOK · SYRE · TARS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| SNDX Current stock | 43/100 | 64/100 | 14/100 | 37/100 | -0.76 | 57.16% | Current |
| SRRK Scholar Rock Holding Corporation | 39/100 | — | 54/100 | 52/100 | 0.84 | 57.45% | SNDX vs SRRK |
| STOK Stoke Therapeutics, Inc. | 42/100 | 22/100 | 47/100 | 59/100 | 0.23 | 53.19% | SNDX vs STOK |
| SYRE Spyre Therapeutics, Inc. | 64/100 | 44/100 | 81/100 | 53/100 | 2.57 | 66.66% | SNDX vs SYRE |
| TARS Tarsus Pharmaceuticals, Inc. | 65/100 | 75/100 | 76/100 | 59/100 | 0.36 | 45.02% | SNDX vs TARS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for SNDX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching SNDX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for SNDX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
SNDX Stock FAQ
What is SNDX stock price today?
Syndax Pharmaceuticals, Inc.'s current stock price is $9.45. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is SNDX bullish or bearish right now?
SNDX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is SNDX's market cap?
SNDX's market cap is $848.51M based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is SNDX's current P/E ratio?
SNDX's current P/E ratio is -3.99 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is SNDX's RSI?
SNDX's 14-day RSI is 26.22 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is SNDX above its 50-day and 200-day moving averages?
SNDX is -38.13% from its 50-day SMA and -52.08% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is SNDX's next earnings date?
SNDX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does SNDX pay a dividend?
SNDX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.